Wendy’s Jumps on Reported $1.4 Billion Trian Takeover Offer
Wendy’s shares jumped after a report of a $1.4 billion Trian takeover offer, putting deal certainty and execution risks in focus.
Eli Lilly’s Retatrutide Data Raises Stakes in the GLP-1 Drug Race
New retatrutide trial data may strengthen Eli Lilly’s position in the GLP-1 market, while raising ex…
GE Vernova’s $9 Billion Trench Deal Puts Grid Investment and Raised Outlook in Focus
GE Vernova’s $9 billion Trench acquisition highlights grid-equipment demand as AI-related power infr…
Wendy’s Shares Jump on Reported $1.4 Billion Trian Takeover Offer
Wendy’s shares moved higher after a report that Nelson Peltz’s Trian Partners offered $1.4 billion t…
Ares Capital’s $2.6 Billion MidCap Financial Deal Sends MFIC Shares Higher
Ares Capital’s $2.6 billion acquisition of MidCap Financial, paid in cash and stock, puts private-cr…
Moderna’s $181.36 Support Level Faces Test After Mixed Melanoma Data
Moderna is holding reported $181.36 support after mixed melanoma vaccine data narrowed the benefit s…
Merck’s Phase III Oncology Results Put Its 2027 Pipeline Under the Microscope
Merck’s TroFuse-005 update puts its oncology pipeline at the center of the post-Keytruda growth deba…
Incyte’s $152 Price Target Holds as H.C. Wainwright Reviews Cancer-Drug Data
H.C. Wainwright kept Incyte’s $152 price target after reviewing new cancer-drug data, signaling cont…
Summit Therapeutics’ $30 Target Holds as Ivonescimab Data Deliver Another Phase 3 Win
Back-to-back bullish analyst calls follow additional ivonescimab data, keeping Summit Therapeutics a…
Pfizer’s Talzenna-Xtandi Approval Expansion Adds New Oncology Catalyst for PFE
The FDA’s expanded approval of Pfizer’s Talzenna-Xtandi combination gives PFE a fresh regulatory cat…